Stammdaten
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.
Unternehmen & Branche
| Name | LIPELLA PHARMACEUTICALS INC. |
|---|---|
| Ticker | LIPO |
| CIK | 0001347242 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 231.042 USD |
| Beta | 1,06 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-09-30 | 10-Q | 216,117 | -1,254,078 | -0.28 | 2,349,810 | 1,487,595 |
| 2025-06-30 | 10-Q | 86,727 | -1,327,486 | -0.31 | 3,720,206 | 2,741,672 |
| 2025-03-31 | 10-Q | 129,390 | -1,306,523 | -0.64 | 4,856,051 | 4,079,204 |
| 2024-12-31 | 10-K | 536,357 | -5,016,264 | -4.79 | 2,673,870 | 1,919,453 |
| 2024-09-30 | 10-Q | 80,380 | -1,444,637 | -1.29 | 2,160,105 | 1,458,918 |
| 2024-06-30 | 10-Q | 136,431 | -938,146 | -0.99 | 2,184,112 | 1,703,798 |
| 2024-03-31 | 10-Q | 145,880 | -1,191,809 | -1.31 | 3,137,157 | 2,561,278 |
| 2023-12-31 | 10-K | 449,617 | -4,618,965 | -6.16 | 3,577,174 | 3,144,448 |
| 2023-09-30 | 10-Q | 104,051 | -1,323,570 | -1.84 | 2,840,945 | 2,221,731 |
| 2023-06-30 | 10-Q | 106,676 | -1,538,686 | -0.27 | 3,489,536 | 3,125,342 |
| 2023-03-31 | 10-Q | 118,048 | -1,067,825 | -0.19 | 4,614,800 | 3,816,410 |
| 2022-12-31 | 10-Q | -2,597,692 | 5,950,110 | 4,675,596 | ||
| 2022-12-31 | 10-K | 184,156 | -2,597,692 | -0.64 | 5,950,110 | 4,675,596 |
| 2022-09-30 | 10-Q | 33,149 | -713,794 | -0.17 | -62,820 | |
| 2022-06-30 | 10-Q | 33,149 | -782,024 | -0.20 | 352,215 | |
| 2022-03-31 | 10-Q | 33,149 | -737,950 | -0.19 | 920,750 | |
| 2021-12-31 | 10-K | 259,347 | -1,865,473 | -0.55 | 2,012,889 | 1,423,552 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
Keine Insider-Käufe/Verkäufe in den letzten 12 Monaten.
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.